WLY vs PSO

For growth investors, Pearson plc (PSO) is the stronger pick with -3.

3% revenue growth year-over-year, versus -10. 4% for John Wiley & Sons, Inc. (WLY). Pearson plc (PSO) offers the better valuation at 17. 8x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate John Wiley & Sons, Inc. (WLY) a "Hold" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pearson plc (PSO) is the cheapest at 17.

8x versus John Wiley & Sons, Inc. at 26. 6x. On forward P/E, John Wiley & Sons, Inc. is actually cheaper at 9. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Pearson plc (PSO) delivered a total return of +45.

0%, compared to -23. 0% for John Wiley & Sons, Inc. (WLY). Over 10 years, the gap is even starker: PSO returned +54. 9% versus WLY's +6. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), John Wiley & Sons, Inc.

(WLY) is the lower-risk stock at 0. 28β versus Pearson plc's 0. 38β — meaning PSO is approximately 35% more volatile than WLY relative to the S&P 500. On balance sheet safety, Pearson plc (PSO) carries a lower debt/equity ratio of 36% versus 120% for John Wiley & Sons, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pearson plc (PSO) is pulling ahead at -3.

3% versus -10. 4% for John Wiley & Sons, Inc. (WLY). On earnings-per-share growth, the picture is similar: John Wiley & Sons, Inc. grew EPS 141. 9% year-over-year, compared to 18. 9% for Pearson plc. Over a 3-year CAGR, PSO leads at 1. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pearson plc (PSO) is the more profitable company, earning 12.

2% net margin versus 5. 0% for John Wiley & Sons, Inc. — meaning it keeps 12. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PSO leads at 15. 2% versus 13. 2% for WLY. At the gross margin level — before operating expenses — WLY leads at 71. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, John Wiley & Sons, Inc.

(WLY) trades at 9. 7x forward P/E versus 21. 9x for Pearson plc — 12. 2x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

John Wiley & Sons, Inc. (WLY) offers the highest yield at 3. 4%, versus 2. 0% for Pearson plc (PSO).

For long-horizon retirement investors, John Wiley & Sons, Inc.

(WLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 4% yield). Both have compounded well over 10 years (WLY: +6. 7%, PSO: +54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Communication Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: WLY is a small-cap income-oriented stock; PSO is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.